Bio Net Receivables vs Good Will Analysis
BIO Stock | USD 293.85 1.88 0.64% |
Bio Rad financial indicator trend analysis is way more than just evaluating Bio Rad Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Rad Laboratories is a good investment. Please check the relationship between Bio Rad Net Receivables and its Good Will accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
Net Receivables vs Good Will
Net Receivables vs Good Will Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Rad Laboratories Net Receivables account and Good Will. At this time, the significance of the direction appears to have strong relationship.
The correlation between Bio Rad's Net Receivables and Good Will is 0.62. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Good Will in the same time period over historical financial statements of Bio Rad Laboratories, assuming nothing else is changed. The correlation between historical values of Bio Rad's Net Receivables and Good Will is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Bio Rad Laboratories are associated (or correlated) with its Good Will. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Good Will has no effect on the direction of Net Receivables i.e., Bio Rad's Net Receivables and Good Will go up and down completely randomly.
Correlation Coefficient | 0.62 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Net Receivables
Good Will
An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.Most indicators from Bio Rad's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Rad Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Bio Rad's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 18th of May 2024, Enterprise Value is likely to grow to about 1 B, while Selling General Administrative is likely to drop about 481.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 1.6B | 1.6B | 1.4B | 769.3M | Total Revenue | 2.9B | 2.8B | 2.7B | 1.4B |
Bio Rad fundamental ratios Correlations
Click cells to compare fundamentals
Bio Rad Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Rad fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Short Long Term Debt Total | 439.8M | 14.1M | 11.0M | 1.2B | 1.4B | 1.5B | |
Other Current Liab | 158.5M | 224.9M | 210.7M | 186.2M | (35.4B) | (33.6B) | |
Total Current Liabilities | 905.5M | 631.5M | 680.9M | 568.7M | 522.8M | 338.4M | |
Total Stockholder Equity | 5.8B | 9.9B | 13.7B | 9.6B | 8.7B | 9.2B | |
Property Plant And Equipment Net | 701.2M | 693.5M | 695.8M | 679.6M | 723.7M | 759.9M | |
Net Debt | (220.9M) | (648.1M) | (459.8M) | 764.0M | 1.0B | 1.1B | |
Retained Earnings | 5.5B | 9.3B | 13.5B | 9.9B | 9.3B | 9.7B | |
Cash | 660.7M | 662.2M | 470.8M | 434.2M | 404.0M | 257.1M | |
Non Current Assets Total | 5.8B | 10.8B | 15.8B | 10.3B | 9.3B | 9.7B | |
Non Currrent Assets Other | (997.7B) | (2.1T) | (3.1T) | (1.8T) | (1.5T) | (1.4T) | |
Cash And Short Term Investments | 1.1B | 996.7M | 875.5M | 1.8B | 1.6B | 1.7B | |
Net Receivables | 392.7M | 419.4M | 423.5M | 494.6M | 500.9M | 272.8M | |
Common Stock Shares Outstanding | 30.2M | 30.2M | 30.2M | 29.8M | 29.2M | 29.1M | |
Liabilities And Stockholders Equity | 8.0B | 13.0B | 17.8B | 13.5B | 12.3B | 12.9B | |
Non Current Liabilities Total | 1.3B | 2.5B | 3.4B | 3.3B | 3.0B | 3.2B | |
Inventory | 554.0M | 622.3M | 572.2M | 719.3M | 780.5M | 819.5M | |
Other Current Assets | 113.3M | 101.5M | 117.8M | 147.8M | 154.0M | 91.6M | |
Other Stockholder Equity | 371.6M | 329.5M | 335.4M | 183.9M | (183.5M) | (174.3M) | |
Total Liab | 2.3B | 3.1B | 4.1B | 3.9B | 3.6B | 3.7B | |
Property Plant And Equipment Gross | 701.2M | 1.5B | 1.5B | 1.5B | 1.8B | 1.9B | |
Total Current Assets | 2.2B | 2.1B | 2.0B | 3.2B | 3.0B | 3.2B | |
Accumulated Other Comprehensive Income | (87.3M) | 282.5M | (175.6M) | (466.8M) | (336.0M) | (319.2M) | |
Short Term Debt | 426.2M | 1.8M | 489K | 465K | 41.4M | 30.8M | |
Accounts Payable | 287.1M | 362.3M | 418.9M | 329.8M | 142.8M | 138.4M | |
Intangible Assets | 145.5M | 199.5M | 253.9M | 332.1M | 320.5M | 188.7M | |
Other Assets | 40.3M | 13K | 82K | 94.6M | 85.1M | 71.4M | |
Long Term Debt | 13.6M | 12.3M | 10.5M | 1.2B | 1.2B | 1.3B | |
Good Will | 264.1M | 291.9M | 347.3M | 406.5M | 413.6M | 339.1M | |
Treasury Stock | (38.4M) | (99.9M) | (106.3M) | (263.6M) | (237.2M) | (225.4M) | |
Property Plant Equipment | 499.3M | 491.4M | 695.8M | 498.6M | 573.4M | 371.9M | |
Current Deferred Revenue | 33.7M | 42.5M | 50.9M | 52.2M | 35.8B | 37.5B | |
Other Liab | 1.2B | 2.4B | 3.4B | 2.0B | 2.3B | 2.4B | |
Short Term Investments | 459.5M | 334.5M | 404.7M | 1.4B | 1.2B | 1.3B | |
Net Tangible Assets | 5.8B | 9.9B | 13.1B | 9.2B | 10.6B | 11.1B | |
Retained Earnings Total Equity | 5.5B | 9.3B | 13.5B | 9.9B | 11.4B | 12.0B | |
Capital Surpluse | 410.0M | 429.4M | 441.7M | 447.5M | 514.6M | 366.5M | |
Deferred Long Term Liab | 997.8M | 2.1B | 3.1B | 1.8B | 2.0B | 2.1B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Bio Stock analysis
When running Bio Rad's price analysis, check to measure Bio Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Rad is operating at the current time. Most of Bio Rad's value examination focuses on studying past and present price action to predict the probability of Bio Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Rad's price. Additionally, you may evaluate how the addition of Bio Rad to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Bio Rad's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.797 | Earnings Share (10.68) | Revenue Per Share 90.024 | Quarterly Revenue Growth (0.1) | Return On Assets 0.0169 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.